-

06:55:35 AM

Latest HALO Stock Market News

HALO - Halozyme Therapeutics Inc.

09/15/21 4:05 PM

Nasdaq : HALO

conferences

Halozyme to Participate in the 2021 Cantor Virtual Global Healthcare Conference

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Elaine Sun, senior vice president and chief financial officer, will present at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 1:20 p.m. Eastern

RHEA-AI

neutral

08/26/21 9:00 AM

Nasdaq : HALO

conferences

Halozyme to Present at Wells Fargo 2021 Virtual Healthcare Conference

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will present at the Wells Fargo 2021 Virtual Healthcare Conference on Friday, September 10, 2021 at 10:40 a.m. Eastern Time / 7:40 a.m.

RHEA-AI

neutral

08/09/21 4:01 PM

Nasdaq : HALO

Halozyme Reports Second Quarter 2021 Results

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the second quarter ended June 30, 2021 and provided an update on its recent corporate activities and outlook. "Our excellent start to 2021 continued in the second quarter with

RHEA-AI

positive

07/30/21 8:00 AM

Nasdaq : HALO

conferences

Halozyme to Participate in Canaccord Genuity 41st Annual Growth Conference

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Elaine Sun, senior vice president and chief financial officer, will virtually represent the company in a fireside chat at the Canaccord Genuity 41 st Annual Growth Conference Securities 2021

RHEA-AI

neutral

07/27/21 4:05 PM

Nasdaq : HALO

conferencesearnings

Halozyme To Host Second Quarter 2021 Financial Results Webcast and Conference Call

Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the second quarter 2021 on Monday, August 9 at 4:30 p.m. ET / 1:30 p.m. PT. Dr. Helen Torley, president and chief executive officer, will lead the call. On the

RHEA-AI

neutral

07/12/21 8:12 AM

Nasdaq : HALO

fda approval

Halozyme Announces Janssen Receives U.S. FDA Approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Janssen Biotech, Inc. (Janssen) received U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) in combination with pomalidomide and

RHEA-AI

very positive

06/22/21 1:48 PM

Nasdaq : HALO

Halozyme Announces Janssen Receives European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formulation for Newly Diagnosed Systemic Light-chain Amyloidosis and Pre-Treated Multiple Myeloma

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the European Commission (EC) has granted the Janssen Pharmaceutical Companies of Johnson & Johnson two marketing authorizations for the subcutaneous formulation of daratumumab, known as DARZALEX

RHEA-AI

very positive

06/22/21 2:22 AM

Nasdaq, NYSE : HALO, PFE

ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of “ultra long-acting” medicines for HIV

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, and Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced a global collaboration and license agreement that gives exclusive access to

RHEA-AI

neutral

06/22/21 2:18 AM

Nasdaq, NYSE : HALO, GSK, PFE

ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of "ultra-long-acting" medicines for HIV

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc ("GSK"), with Pfizer Inc. and Shionogi Limited as shareholders, and Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced a global collaboration and

RHEA-AI

neutral

06/01/21 4:01 PM

Nasdaq : HALO

Halozyme Highlights Data Presentations by Collaborators for Therapies Utilizing ENHANZE® at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced abstracts and presentations by its collaborators for the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 4-8, 2021.Janssen Research & Development, LLC

RHEA-AI

neutral

HALO Data:

IndustryBiological Product (except Diagnostic) Manufacturing
Websitewww.halozyme.com
CeoHelen Torley
Security nameHalozyme Therapeutics Inc.
Issue typecs
SectorManufacturing
Sic code2836
Employees136
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
Address11388 Sorrento Valley Rd
StateCalifornia
CitySan Diego
Zip92121-1345
CountryUS
Phone18587948889

HALO Description:

Halozyme is a biopharmaceutical company focused on bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients' lives while helping its partners achieve global commercial success. Halozyme's proprietary enzyme rHuPH20 forms the basis of the ENHANZE® technology and is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion, argenx and Horizon Therapeutics. Halozyme derives revenues from these collaborations in the form of milestones and royalties as the Company's partners make progress developing and commercializing their products being developed with ENHANZE®. Halozyme is headquartered in San Diego.